{"nctId":"NCT00420212","briefTitle":"Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis","startDateStruct":{"date":"2007-01"},"conditions":["Relapsing-Remitting Multiple Sclerosis"],"count":1234,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"BG00012 240 mg Twice Daily (BID)","type":"EXPERIMENTAL","interventionNames":["Drug: BG00012"]},{"label":"BG00012 240 mg 3 Times Daily (TID)","type":"EXPERIMENTAL","interventionNames":["Drug: BG00012"]}],"interventions":[{"name":"BG00012","otherNames":["dimethyl fumarate","Tecfidera®"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Unless otherwise specified, to be eligible to participate in this study, candidates must meet the following eligibility criteria at the time of the randomization:\n* Must have a confirmed diagnosis of RRMS according to McDonald criteria #1-4.\n* Must have a baseline EDSS between 0.0 and 5.0, inclusive.\n* Must have relapsing-remitting disease course.\n\nKey Exclusion Criteria:\n\n* Unless otherwise specified, candidates will be excluded from study entry if any of the following exclusion criteria exist at randomization:\n* Other chronic disease of the immune system, malignancies, acute urologic, pulmonary, gastrointestinal disease.\n* Pregnant or nursing women.\n\nNote: Other protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Subjects Relapsed","description":"A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurolgic evaluation committee. The proportion of subjects with a relapse was estimated using the Kaplan-Meier method, which was based on the time-to-first-relapse survival distribution.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.461","spread":null},{"groupId":"OG001","value":"0.270","spread":null},{"groupId":"OG002","value":"0.260","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of New or Newly Enlarging T2 Hyperintense Lesions","description":"The number of new or newly enlarging T2 hyperintense lesions at 2 years that developed in each subject compared to baseline assessed on brain magnetic resonance imaging (MRI) scans. The estimates of mean T2 lesion count were calculated from a negative binomial regression model adjusted for region and baselineT2 lesion volume","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.0","spread":null},{"groupId":"OG001","value":"2.6","spread":null},{"groupId":"OG002","value":"4.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Gadolinium-enhancing T1-weighted Lesions","description":"The number of Gd-enhancing lesions was assessed using brain MRI scans following administration of gadolinium, a contrast agent. The mean number of Gd-enhancing lesions at 2 years was the average of the number of lesions at 2 years in a treatment group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"4.15"},{"groupId":"OG001","value":"0.1","spread":"0.63"},{"groupId":"OG002","value":"0.5","spread":"1.73"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Gadolinium (Gd)-Enhancing Lesions","description":"Note: This outcome measure represents the categorical analysis for the previously listed secondary outcome measure \"Number of Gadolinium-enhancing T1-weighted lesions\"","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"142","spread":null},{"groupId":"OG002","value":"130","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Relapse Rate","description":"A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurologic evaluation committee. The adjusted annualized relapse rate was calculated from a negative binomial regression model, adjusted for baseline EDSS (≤ 2.0 vs. \\>2.0), age (\\<40 versus ≥40 years), region, and the number of relapses in the 1 year prior to enrollment.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.364","spread":null},{"groupId":"OG001","value":"0.172","spread":null},{"groupId":"OG002","value":"0.189","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS)","description":"The EDSS is based on a standardized neurological examination and focuses on symptoms that commonly occur in MS. EDSS scores range from 0.0 (normal) to 10.0 (death due to MS). Disability progression was defined as ≥ 1.0 point increase in subjects with a baseline EDSS of ≥1.0, or a ≥1.5 point increase in subjects with a baseline EDSS = 0, and required that the increase from baseline was confirmed ≥12 weeks later. The proportion of subjects with confirmed (12-week) disability progression was estimated using the Kaplan-Meier method, which was based on the time-to-first-progression survival distribution.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.271","spread":null},{"groupId":"OG001","value":"0.164","spread":null},{"groupId":"OG002","value":"0.177","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":86,"n":408},"commonTop":["MULTIPLE SCLEROSIS RELAPSE","FLUSHING","NASOPHARYNGITIS","HEADACHE","DIARRHEA"]}}}